Shorter chemo shows promise for kids with hodgkin lymphoma
NCT ID NCT00846742
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial is testing a shorter, more intense chemotherapy regimen called Stanford V in children and young adults with favorable Hodgkin lymphoma. Those who still have signs of cancer after 8 weeks of chemo also receive low-dose radiation to the affected areas. The goal is to see if this approach can improve the complete response rate while reducing the need for longer treatment and its side effects. The study enrolled 88 participants aged 21 and younger.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stanford V chemotherapy (a combination of vinblastine, doxorubicin, vincristine, bleomycin, mechlorethamine, etoposide, and prednisone) with or without low-dose radiation therapy
What this could lead to
If successful, this could offer a shorter, less toxic treatment option for children with favorable Hodgkin lymphoma, potentially reducing long-term side effects while maintaining high cure rates.
What could go wrong
This is a phase 2 trial with only 88 participants, so results are preliminary. The chemotherapy still carries risks like infection, bleeding, and fertility issues, and some children may still need radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Illinois at OSF St. Francis Medical Center
Peoria, Illinois, 61637, United States
-
Dana-Farber Harvard Cancer Center
Boston, Massachusetts, 02115, United States
-
Maine Children's Cancer Program (MCCP)
Scarborough, Maine, 04074, United States
-
Packard Children's Hospital, Stanford University
Palo Alto, California, 94304, United States
-
Rady Children's Hospital- San Diego
San Diego, California, 92123, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States